Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
2001 1
2002 3
2004 1
2005 1
2006 2
2007 2
2008 4
2009 4
2010 6
2011 5
2012 6
2013 3
2014 2
2015 2
2016 3
2017 10
2018 14
2019 8
2020 7
2021 3
2022 6
2023 6
2024 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

92 results

Results by year

Filters applied: . Clear all
Page 1
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.
Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, Richeldi L, Kolb M, Tetzlaff K, Stowasser S, Coeck C, Clerisme-Beaty E, Rosenstock B, Quaresma M, Haeufel T, Goeldner RG, Schlenker-Herceg R, Brown KK; INBUILD Trial Investigators. Flaherty KR, et al. N Engl J Med. 2019 Oct 31;381(18):1718-1727. doi: 10.1056/NEJMoa1908681. Epub 2019 Sep 29. N Engl J Med. 2019. PMID: 31566307 Clinical Trial.
Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.
Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, Raghu G, Sauter W, Girard M, Alves M, Clerisme-Beaty E, Stowasser S, Tetzlaff K, Kuwana M, Maher TM; SENSCIS Trial Investigators. Distler O, et al. N Engl J Med. 2019 Jun 27;380(26):2518-2528. doi: 10.1056/NEJMoa1903076. Epub 2019 May 20. N Engl J Med. 2019. PMID: 31112379 Free article. Clinical Trial.
Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
Wells AU, Flaherty KR, Brown KK, Inoue Y, Devaraj A, Richeldi L, Moua T, Crestani B, Wuyts WA, Stowasser S, Quaresma M, Goeldner RG, Schlenker-Herceg R, Kolb M; INBUILD trial investigators. Wells AU, et al. Lancet Respir Med. 2020 May;8(5):453-460. doi: 10.1016/S2213-2600(20)30036-9. Epub 2020 Mar 5. Lancet Respir Med. 2020. PMID: 32145830 Clinical Trial.
Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.
Idiopathic Pulmonary Fibrosis Clinical Research Network; Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ. Idiopathic Pulmonary Fibrosis Clinical Research Network, et al. N Engl J Med. 2012 May 24;366(21):1968-77. doi: 10.1056/NEJMoa1113354. Epub 2012 May 20. N Engl J Med. 2012. PMID: 22607134 Free PMC article. Clinical Trial.
Cobalt related interstitial lung disease.
Adams TN, Butt YM, Batra K, Glazer CS. Adams TN, et al. Among authors: glazer cs. Respir Med. 2017 Aug;129:91-97. doi: 10.1016/j.rmed.2017.06.008. Epub 2017 Jun 13. Respir Med. 2017. PMID: 28732841 Free article. Review.
Respiratory protection.
Martyny J, Glazer CS, Newman LS. Martyny J, et al. Among authors: glazer cs. N Engl J Med. 2002 Sep 12;347(11):824-30. doi: 10.1056/NEJMra012670. Epub 2002 Sep 9. N Engl J Med. 2002. PMID: 12226154 Review. No abstract available.
Occupational interstitial lung disease.
Glazer CS, Newman LS. Glazer CS, et al. Clin Chest Med. 2004 Sep;25(3):467-78, vi. doi: 10.1016/j.ccm.2004.04.004. Clin Chest Med. 2004. PMID: 15331187 Review.
Effect of antigen removal in hypersensitivity pneumonitis.
Robertshaw MJ, Gorman A, Glazer CS, Adams TN. Robertshaw MJ, et al. Among authors: glazer cs. BMC Pulm Med. 2024 Aug 20;24(1):398. doi: 10.1186/s12890-024-03098-3. BMC Pulm Med. 2024. PMID: 39164720 Free PMC article.
92 results